Masimo appointed Katie Szyman as its next chief executive officer after a proxy fight forced out the company’s founder.

Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...

(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device ...

Masimo (Nasdaq: MASI) + Masimo Corporation $172.4 1.44% Open 173.198 Day High 175.067 52 Week High 147.89 52 Week Low 75.22 announced today that it appointed Katie Szyman as its new CEO, effective Feb ...

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide ...

Masimo (MASI) announced that Katie Szyman has been appointed the next Chief Executive Officer of the Company. Interim CEO Michelle Brennan has ...

Szyman, an industry leader with deep med-tech roots, to guide the company as it seeks to rebuild its reputation and revenues following a gritty two-year battle for control. Current CEO Michelle ...

Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...

Telehealth and Telecare News since 2005 ...

Needham analyst Michael Matson has maintained their neutral stance on MASI stock, giving a Hold rating on January 17.Invest with Confidence: ...